FDA approves COVID-19 antigen test, first chikungunya vaccine
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-home test to successfully complete traditional premarket review.
In other news, the agency yesterday approved the first chikungunya vaccine for adults at increased risk of exposure to the virus, primarily through travel to regions of Africa, Southeast Asia and the Americas where mosquitos carry the virus. The Centers for Disease Control and Prevention last year reported 81 travel-associated cases. Locally acquired cases were reported in Florida in 2014 and Texas in 2015.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…